Stocks in Action USA: Eton Pharmaceuticals, Heartflow, Nu Holdings

Eton Pharmaceuticals (ETON) nearly doubles revenue and aims for a 35% EBITDA margin! Eton Pharmaceuticals has achieved a significant growth surge in the second quarter of 2026, driven by strong demand for therapies for rare diseases: Revenue nearly doubled, increasing by 99% to $37.6 million, while the company turned a net loss of $2.6 million from the previous year into a net profit of $11.6 million. Particularly important was the successful relaunch of Hemangeol through its own Eton Cares distribution model, while the in-licensing of ASN-001...